Literature DB >> 26269750

PC4 induces lymphangiogenesis dependent VEGF-C/VEGF-D/VEGFR-3 axis activation in lung adenocarcinoma.

Shaolin Tao1, Jie Yu1, Yi Xu1, Bo Deng1, Tianyu Sun1, Pingping Hu1, Zhuanqin Wei1, Jingge Zhang1, Ruwen Wang1, Chunmeng Shi2, Qunyou Tan1.   

Abstract

Human transcriptional positive cofactor 4 (PC4) is a novel marker for diagnosis and treatment of advanced human cancers metastasis. In human lung adenocarcinoma, tumor lymphangiogenesis, an important early event, can promotes lymphatic metastasis, while it has been reported that VEGF-C/VEGF-D/VEGFR-3 axis plays an important role in lymphangiogenesis. The proposed study aims to explore whether PC4 correlates with VEGF-C/VEGF-D/VEGFR-3 axis of lymphangiogenesis in the lymph node metastasis during lung adenocarcinoma. Here, small interfering RNA technique was employed to investigate the relationship of PC4 and the VEGF-C/VEGF-D/VEGFR-3 axis in lung adenocarcinoma cell lines as well as tumor xenografts of mice model. And then mRNA and protein levels of PC4, VEGF-C, VEGF-D and VEGFR-3 were analyzed. Moreover, the correlation between PC4 expression and lymphatic vessel density or the rate of metastatsis in vivo was also revealed. Down-regulating PC4 expression resulted in the lower expression of VEGFC, VEGF-D and VEGFR-3 in mRNA and protein levels, and PC4 expression was significantly related with the factor of VEGF-C/VEGF-D/VEGFR-3 axis expression (P<0.05). Meanwhile, high expression level of PC4 was accompanied by the higher density of tumor lymphatic vessels and the rate of metastatsis in vivo (P<0.05). PC4 expression correlated with the levels of VEGF-C, VEGF-D and VEGFR-3 during the development of lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma in vitro and in vivo, which may be a novel marker in the development of lymphangiogenesis and lymphatic metastasis of tumors.

Entities:  

Keywords:  PC4; VEGF-C/VEGF-D/VEGFR-3 axis; lung adenocarcinoma; lymphangiogenesis; metastasis

Year:  2015        PMID: 26269750      PMCID: PMC4529610     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  18 in total

1.  Transcriptional coactivator PC4, a chromatin-associated protein, induces chromatin condensation.

Authors:  Chandrima Das; Kohji Hizume; Kiran Batta; B R Prashanth Kumar; Shrikanth S Gadad; Semanti Ganguly; Stephanie Lorain; Alain Verreault; Parag P Sadhale; Kunio Takeyasu; Tapas K Kundu
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

2.  Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.

Authors:  Yukuan Feng; Wei Wang; Jing Hu; Jing Ma; Yafang Zhang; Jianguo Zhang
Journal:  Anat Rec (Hoboken)       Date:  2010-05       Impact factor: 2.064

3.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.

Authors:  T Mäkinen; T Veikkola; S Mustjoki; T Karpanen; B Catimel; E C Nice; L Wise; A Mercer; H Kowalski; D Kerjaschki; S A Stacker; M G Achen; K Alitalo
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

Review 4.  Sub1/PC4 a chromatin associated protein with multiple functions in transcription.

Authors:  Christine Conesa; Joël Acker
Journal:  RNA Biol       Date:  2010-05-09       Impact factor: 4.652

5.  The transcriptional coactivator PC4/Sub1 has multiple functions in RNA polymerase II transcription.

Authors:  Olga Calvo; James L Manley
Journal:  EMBO J       Date:  2005-02-03       Impact factor: 11.598

6.  Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways.

Authors:  Ahmad Salameh; Federico Galvagni; Monia Bardelli; Federico Bussolino; Salvatore Oliviero
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

7.  Blocking the path of lymphatic vessels.

Authors:  Mihaela Skobe; Reza Dana
Journal:  Nat Med       Date:  2009-09       Impact factor: 53.440

8.  Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma.

Authors:  Jen-Liang Su; Jin-Yuan Shih; Men-Luh Yen; Yung-Ming Jeng; Cheng-Chi Chang; Chang-Yao Hsieh; Lin-Hung Wei; Pan-Chyr Yang; Min-Liang Kuo
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

9.  Purification, cloning, and characterization of a human coactivator, PC4, that mediates transcriptional activation of class II genes.

Authors:  H Ge; R G Roeder
Journal:  Cell       Date:  1994-08-12       Impact factor: 41.582

Review 10.  Role of lymphangiogenesis in lung cancer.

Authors:  Bozena Weryńska; Piotr Dziegiel; Renata Jankowska
Journal:  Folia Histochem Cytobiol       Date:  2009-01       Impact factor: 1.698

View more
  10 in total

1.  A biochemical and biophysical model of G-quadruplex DNA recognition by positive coactivator of transcription 4.

Authors:  Wezley C Griffin; Jun Gao; Alicia K Byrd; Shubeena Chib; Kevin D Raney
Journal:  J Biol Chem       Date:  2017-04-17       Impact factor: 5.157

2.  MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.

Authors:  B V S K Chakravarthi; M T Goswami; S S Pathi; A D Robinson; M Cieślik; D S Chandrashekar; S Agarwal; J Siddiqui; S Daignault; S L Carskadon; X Jing; A M Chinnaiyan; L P Kunju; N Palanisamy; S Varambally
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

3.  CCR7 promote lymph node metastasis via regulating VEGF-C/D-R3 pathway in lung adenocarcinoma.

Authors:  Jie Yu; Shaolin Tao; Pingping Hu; Ruwen Wang; Chunshu Fang; Yi Xu; Di Qi; Zhuanqin Wei; Jingge Zhang; Qunyou Tan
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

4.  A Novel Role of VEGFC in Cerebral Ischemia With Lung Injury.

Authors:  Mu-Dong Wen; Ya Jiang; Jin Huang; Mohammed Al-Hawwas; Qi-Qin Dan; Rui-An Yang; Bing Yuan; Xiao-Ming Zhao; Ling Jiang; Ming-Mei Zhong; Liu-Lin Xiong; Yun-Hui Zhang
Journal:  Front Neurosci       Date:  2019-05-15       Impact factor: 4.677

5.  Transcriptional positive cofactor 4 promotes breast cancer proliferation and metastasis through c-Myc mediated Warburg effect.

Authors:  Peng Luo; Chi Zhang; Fengying Liao; Long Chen; Zhenyu Liu; Lei Long; Zhongyong Jiang; Yawei Wang; Ziwen Wang; Zujuan Liu; Hongming Miao; Chunmeng Shi
Journal:  Cell Commun Signal       Date:  2019-04-16       Impact factor: 5.712

6.  Human Positive Coactivator 4 Affects the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma via the mTOR/P70s6k Signaling Pathway.

Authors:  Xingxing Su; Yishi Yang; Le Ma; Peng Luo; Kaicheng Shen; Haisu Dai; Yan Jiang; Ling Shuai; Zhipeng Liu; Jinshan You; Ke Min; Chunmeng Shi; Zhiyu Chen
Journal:  Onco Targets Ther       Date:  2020-11-26       Impact factor: 4.147

7.  The Human Positive Cofactor 4 is a Promising Chemotherapeutic Target in Lung Adenocarcinoma.

Authors:  Tianyu Sun; Jingge Zhang; Xiaoqing Fan; Tan Long; Shaolin Tao; Poming Kang; Qunyou Tan
Journal:  J Oncol       Date:  2021-12-03       Impact factor: 4.375

8.  Study on the Correlation Between CT Features and Vascular Tumor Thrombus Together With Nerve Invasion in Surgically Resected Lung Adenocarcinoma.

Authors:  Yu Song; Daiwen Chen; Duohuang Lian; Shangwen Xu; Hui Xiao
Journal:  Front Surg       Date:  2022-06-28

9.  Efficacy of a small molecule inhibitor of the transcriptional cofactor PC4 in prevention and treatment of non-small cell lung cancer.

Authors:  Yan Zhang; Andrei Pavlov; Sohail Malik; Hong Chen; Nancy Kim; Ziqing Li; Xiaohong Zhang; Melvin L DePamphilis; Robert G Roeder; Hui Ge
Journal:  PLoS One       Date:  2020-03-31       Impact factor: 3.240

10.  Co-expression of VEGF-C and survivin predicts poor prognosis in esophageal squamous cell carcinoma.

Authors:  Yun-Zhu Zeng; Yong-Qu Zhang; Xue-Qiong Lin; Jiong-Yu Chen; Fan Zhang; Jian-Ling Zhu; Xiao-Long Wei
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.